Researcher looking through a microscope and holding a vial

Hematologic Malignancies and Cellular Therapy

As leaders in hematologic oncology, stem cell, and bone marrow transplantation and immunotherapy, Duke Cancer Institute’s Hematologic Malignancies and Cellular Therapy (HMCT) disease group is internationally recognized for its novel approaches to treating leukemia, lymphoma, myeloma, and other life-threatening blood-related cancers.

Donate to Support Hematologic Malignancies and Cellular Therapy Research at Duke

Make a Gift

Related News Results

This page was reviewed on 01/17/2024